|Articles|March 13, 2020
UHPLC Analysis of mAbs
Author(s)YMC Europe GmbH
This note using YMC-Triart Bio C4 shows a robust separation at high temperatures for three commercially available mAbs: ofatumumab, palivizumab, and panitumumab.
Newsletter
Join the global community of analytical scientists who trust LCGC for insights on the latest techniques, trends, and expert solutions in chromatography.
Related Content
Trending on LCGC International
1
Volatile Organic Compound Profiling of Commercial Kombucha Using GC-TOF-MS and GC×GC-TOF-MS
2
A Question of Balance? Part III: Weighing Isn’t an Uncertain Process, Is It?
3
Leaks and Obstructions: Troubleshooting Common Problems Close to the Point of Sample Injection
4
Deep In The Heart of Texas: Pittcon 2026
5